The pros and cons of new tests that claim to detect cancer in its early stages.
In the ever-changing health care landscape, early-detection blood tests for cancer are gaining traction. Although the tests are not yet approved by the Food and Drug Administration (FDA), manufacturers are heavily lobbying legislators, spending half a million dollars at a clip to get the agency’s crucial blessing. Once the FDA gives the go-ahead, and Medicare picks up the tab, it will be a never-ending gravy train. Nevertheless, the jury is still out concerning the efficacy of such a medical procedure.
There is no shortage of developers eager to get in on what could be a lucrative product, but as manufacturers try to elbow each other out of the way, new data suggest the test’s effectiveness is mixed.
Cancer — the Key Is Early Detection
The move…




